| Effect of Traditional Chinese Medicine on Outcomes in Patients With Mild/Moderate Chronic Obstructive Pulmonary Disease (NCT01486186) | Henan University of Traditional Chinese Medicine | 2011-12-01 |
| Assessment of Comorbidities in Chronic Obstructive Pulmonary Disease (COPD) in European Symptomatic Subjects From Primary Care (NCT01516528) | GlaxoSmithKline | 2011-11-17 |
| Observational Study of Adherence to LABA / LAMA in Chronic Obstructive Pulmonary Disease (COPD) (NCT01937390) | Boehringer Ingelheim | 2011-11-06 |
| Do the SPPB and 4-metre Gait Speed Predict Hospital Readmission in Patients Hospitalised for Acute Exacerbation if COPD? (NCT01507415) | Royal Brompton & Harefield NHS Foundation Trust | 2011-11-01 |
| Treatment of Metabolic Alkalosis With Acetazolamide. Effect on the Length of Mechanical Ventilation. (NCT01499485) | Hospital Son Llatzer | 2011-11-01 |
| Assessment of Health-status of Patients With Chronic Obstructive Pulmonary Disease (COPD) on Maintenance Therapy With Spiriva HH Measured by COPD Assessment Test (CAT) Test (NCT01644734) | Boehringer Ingelheim | 2011-11-01 |
| Does Pulmonary Daoyin of China Give Additional Benefit Over Usual Therapy in Management of Stable Chronic Obstructive Pulmonary Disease? (NCT01482000) | Henan University of Traditional Chinese Medicine | 2011-11-01 |
| Life-long Monitoring of COPD in Veneto Region (NCT01513980) | Regione Veneto | 2011-11-01 |
| Tiotropium (18mcg) in Chronic Obstructive Pulmonary Disease (COPD) Patients With a Respiratory Infection (NCT01483625) | Boehringer Ingelheim | 2011-11-01 |
| A Study to Look at How GSK1325756 is Taken up by the Body When Given by Mouth When Stomach Acid is Reduced (NCT01453478) | GlaxoSmithKline | 2011-10-12 |
| Assessment of Lung Function After Single Inhalations of a Bronchodilator From 2 Configurations a Dry Powder Inhaler. (NCT01521390) | GlaxoSmithKline | 2011-10-12 |
| ADESPI: Adherence to Spiriva® in Patients With COPD (Chronic Obstructive Pulmonary Disease), Measured by Morisky-8 (MMAS-8) Scale, in Routine Medical Practice (NCT01388166) | Boehringer Ingelheim | 2011-09-01 |
| Nutritional Rehabilitation in Chronic Obstructive Pulmonary Disease (COPD) Patients With Muscle Atrophy (NCT01344135) | Maastricht University Medical Center | 2011-09-01 |
| Tiotropium+Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD) (NCT01431274) | Boehringer Ingelheim | 2011-09-01 |
| Muscle Metabolism and Oxygenation During Localized Fatigue-exercise in COPD (NCT01909544) | Laval University | 2011-09-01 |
| Tiotropium +Olodaterol Fixed Dose Combination (FDC) Versus Tiotropium and Olodaterol in Chronic Obstructive Pulmonary Disease (COPD) (NCT01431287) | Boehringer Ingelheim | 2011-09-01 |
| Non-invasive Ventilation System in Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) (NCT01355978) | Breathe Technologies, Inc. | 2011-08-01 |
| Long-term Safety Study for GSK573719/GW642444 in Japanese (NCT01376388) | GlaxoSmithKline | 2011-08-01 |
| Chronic Obstructive Pulmonary Disease and Pulmonary Hypertension: Prevalence and Quality of Life (NCT01423071) | Wissenschaftliches Institut Bethanien e.V | 2011-08-01 |
| Chest Wall Motion Analysis in Disease (NCT02958683) | Heart of England NHS Trust | 2011-07-01 |
| Evaluate the Efficacy and Safety of GSK573719 Delivered Via a Novel Dry Powder Inhaler in Subjects With COPD (NCT01387230) | GlaxoSmithKline | 2011-07-01 |
| A Randomized, Double Blind, Placebo Controlled, Incomplete Block, Crossover, Dose Ranging Study to Evaluate the Dose Response of GSK573719 Administered Once or Twice Daily Over 7 Days in Patients With Chronic Obstructive Pulmonary Disease (COPD) (NCT01372410) | GlaxoSmithKline | 2011-07-01 |
| A Study To Determine Effects Of Fluticasone Propionate On Sputum Neutrophils After Inhaled Lipopolysaccharide Challenge In Volunteers (NCT01364519) | Pfizer | 2011-07-01 |
| A Study to Compare the Impact of Fulticasone Furoate/Vilanterol vs. Tiotropium on Arterial Stiffness in COPD (NCT01395888) | GlaxoSmithKline | 2011-06-30 |
| Single Portable Pulse-dose-conserving Device vs. Combined Use of Stationary and Portable. (NCT02079753) | Hospital Son Espases | 2011-06-01 |
| The Effect of Spa Treatment on Chronic Obstructive Pulmonary Disease (NCT01296854) | Centre Hospitalier Universitaire de Nīmes | 2011-05-01 |
| Study To Evaluate The Efficacy And Safety Of PH-797804 For 12 Weeks In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD) Taking Salmeterol Xinafoate/Fluticasone Propionate Combination (NCT01321463) | Pfizer | 2011-05-01 |
| Single Limb Resistance Training in Patients With Chronic Obstructive Pulmonary Disease (COPD) (NCT01354067) | Umeå University | 2011-05-01 |
| In-home Evaluation of a Noninvasive Open Ventilation System in Patients With Severe Respiratory Insufficiency (NCT01347931) | Breathe Technologies, Inc. | 2011-05-01 |
| A Study to Determine the Excretion Balance and Pharmacokinetics of 14C-GSK573719 (NCT01362257) | GlaxoSmithKline | 2011-04-29 |
| A 24-week Study of Fluticasone Furoate/Vilanterol Inhalation Powder in Subjects of Asian Ancestry With COPD (NCT01376245) | GlaxoSmithKline | 2011-04-01 |
| Is the Short Physical Performance Battery a Useful Outcome Measure in Chronic Obstructive Pulmonary Disease (NCT01515709) | Royal Brompton & Harefield NHS Foundation Trust | 2011-04-01 |
| Study Evaluating the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD) (NCT01323621) | GlaxoSmithKline | 2011-03-18 |
| An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444.Study B (NCT01323660) | GlaxoSmithKline | 2011-03-16 |
| A 24-week Arterial Stiffness Study With Fluticasone Furoate/Vilanterol in COPD (NCT01336608) | GlaxoSmithKline | 2011-03-04 |
| A 24-week Evaluation of GSK573719/Vilanterol (62.5/25mcg) and Components in COPD (NCT01313650) | GlaxoSmithKline | 2011-03-01 |
| A 24-week Evaluation of GSK573719/Vilanterol (125/25mcg) and Components in COPD (NCT01313637) | GlaxoSmithKline | 2011-03-01 |
| Short-term Telehealth Follow up After Hospital Discharge for Chronic Obstructive Pulmonary Disease Exacerbation (NCT01489241) | Regional Health Authority of Sterea & Thessaly | 2011-03-01 |
| 24-week Trial Comparing GSK573719/GW642444 With GW642444 and With Tiotropium in Chronic Obstructive Pulmonary Disease (NCT01316900) | GlaxoSmithKline | 2011-03-01 |
| An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study A (NCT01328444) | GlaxoSmithKline | 2011-03-01 |
| SMS Reminder to Assess Adherence (NCT01308476) | Boehringer Ingelheim | 2011-03-01 |
| Outcomes for Chronic Obstructive Pulmonary Disease Moderate Exacerbators Initiating Treatment (NCT01395875) | GlaxoSmithKline | 2011-03-01 |
| 24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease (NCT01316913) | GlaxoSmithKline | 2011-03-01 |
| Telehome Monitoring for Chronic Disease Management (NCT02035566) | University of Maryland, Baltimore | 2011-02-01 |
| A Study to Evaluate the 24 Hour Spirometric Effect (FEV1) of Fluticasone Furoate/Vilanterol Inhalation Powder (100mcg Fluticasone Furoate (FF)/25mcg Vilanterol (VI)) Compared With Salmeterol/Fluticasone Propionate Inhalation Powder (50mcg Salmeterol/500mcg Fluticasone Propionate (FP)) (NCT01342913) | GlaxoSmithKline | 2011-02-01 |
| Study to Evaluate the Effect of Fluticasone Furoate/Vilanterol on Survival in Subjects With Chronic Obstructive Pulmonary Disease (NCT01313676) | GlaxoSmithKline | 2011-01-25 |
| Epidemiological Study on the Relationship Between Respiratory Health and Air Pollution From Industrial Sources (NCT02490553) | University Hospital, Lille | 2011-01-01 |
| Eccentric Exercise Training as Novel Rehabilitation for Chronic Obstructive Pulmonary Disease (COPD) (NCT01077102) | McGill University Health Centre/Research Institute of the McGill University Health Centre | 2011-01-01 |
| A 52-Week, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety and Tolerability of GSK573719/GW642444 and GSK573719 in Subjects With Chronic Obstructive Pulmonary Disease (COPD) (NCT01316887) | GlaxoSmithKline | 2011-01-01 |
| Korean Chronic Obstructive Pulmonary Disease(COPD) Assessment Test Validation Study (NCT01424527) | GlaxoSmithKline | 2010-12-01 |
| A Study to Assess the Effects of Repeat Doses of Fluticasone Furoate and GW642444M Combination in Healthy Subjects and in Subjects With Severe Impairment. (NCT01266980) | GlaxoSmithKline | 2010-11-18 |
| Blood Levels and Effects of GSK1325756 in Healthy Adult Volunteers Aged 40 to 80 Years Old (NCT01267006) | GlaxoSmithKline | 2010-11-05 |
| Randomised, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-centre, Dose Ranging Study to Evaluate the Efficacy and Safety of Losmapimod Tablets Administered Twice Daily Compared With Placebo for 24 Weeks in Adult Subjects With Chronic Obstructive Pulmonary Disease (COPD). (NCT01218126) | GlaxoSmithKline | 2010-11-04 |
| Clinical and Economic Burden of Patients With Chronic Obstructive Pulmonary Disease in a Medicaid Population (NCT01615783) | GlaxoSmithKline | 2010-11-01 |
| Chronic Obstructive Pulmonary Disease (COPD)-Related Outcomes and Costs for Patients on Combination Fluticasone Propionate-Salmeterol Xinafoate 250/50mcg Versus Anticholinergics in a COPD-Comorbid Depression/Anxiety Population (NCT01337336) | GlaxoSmithKline | 2010-10-01 |
| Tiotropium Respimat Pharmacokinetic Study in COPD (NCT01222533) | Boehringer Ingelheim | 2010-10-01 |
| Risk of Re-Hospitalization in Patients With Chronic Obstructive Pulmonary Disease (COPD) Post Exacerbation (NCT01381458) | GlaxoSmithKline | 2010-09-01 |
| Nitric Oxide Bioavailability in Chronic Obstructive Pulmonary Disease (COPD) (NCT01398943) | Augusta University | 2010-09-01 |
| Behavioral Intervention to Maintain Physical Capacity and Activity in Patients With Chronic Obstructive Pulmonary Disease (COPD) (NCT01539434) | Uppsala University | 2010-09-01 |
| Multicomponent Intervention to Decrease Chronic Obstructive Pulmonary Disease (COPD)-Related Hospitalizations (NCT01058486) | Mayo Clinic | 2010-09-01 |
| Helium-3 MRI Imaging Study in COPD (NCT02207452) | GlaxoSmithKline | 2010-08-05 |
| Predictive Ability of the Chronic Obstructive Pulmonary Disease (COPD) Assessment Test (CAT) for Acute Exacerbations (PACE) in Patients With COPD (NCT01254032) | GlaxoSmithKline | 2010-08-01 |
| A Long-term Safety Study of Fluticasone Furoate (FF)/GW642444 in Japanese Subjects With COPD (NCT01192191) | GlaxoSmithKline | 2010-08-01 |
| Fluticasone Propionate/Salmeterol Combination 250/50 DISKUS in the Exercise Endurance Time in Patients With Chronic Obstructive Pulmonary Disease (NCT01124422) | GlaxoSmithKline | 2010-07-19 |
| Study in COPD (Chronic Obstructive Pulmonary Disease) Subjects to Investigate Safety, Tolerability, and Pharmacokinetics of Ciprofloxacin After Single Dose Inhalations of 50 mg and 75 mg Ciprofloxacin Inhalation Powder (NCT01168895) | Bayer | 2010-07-01 |
| Does Positive Expiratory Pressure Mask Therapy Improve Recovery From Acute Exacerbations of Chronic Obstructive Pulmonary Disease? (NCT01101282) | La Trobe University | 2010-07-01 |
| Breathing Helium-Hyperoxia During Exercise in Patients With Chronic Obstructive Pulmonary Disease (NCT01283685) | West Park Healthcare Centre | 2010-07-01 |
| A Study for Disease Profiling of Asthma and Chronic Obstructive Pulmonary Disease (NCT01274507) | Janssen Research & Development, LLC | 2010-07-01 |
| A Single Dose Study to Determine the Excretion, Balance and Metabolic Disposition of Radiolabelled GW642444. (NCT01286831) | GlaxoSmithKline | 2010-05-18 |
| Drug Use Survey of RESPIMAT in Patients With COPD (NCT01145053) | Boehringer Ingelheim | 2010-05-01 |
| Comparison of Tiotropium in the HandiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease (NCT01126437) | Boehringer Ingelheim | 2010-05-01 |
| Relative Bioavailability of of Olodaterol and Ketoconazole (NCT01153711) | Boehringer Ingelheim | 2010-05-01 |
| Relative Bioavailability of Olodaterol and Fluconazole (NCT01153724) | Boehringer Ingelheim | 2010-05-01 |
| Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study (NCT01110200) | GlaxoSmithKline | 2010-04-30 |
| GSK573719 IV Enabling Study (NCT01110018) | GlaxoSmithKline | 2010-04-28 |
| Pharmacokinetic and Safety of GSK573719 and GW642444 Administered Individually and Concurrently, With Verapamilin in Healthy Subjects (NCT01128634) | GlaxoSmithKline | 2010-03-04 |
| Simvastatin Therapy for Moderate and Severe COPD (NCT01061671) | University of Minnesota | 2010-03-01 |
| A Study To Investigate The Safety, Toleration And Efficacy of PF00610355 In Chronic Obstructive Pulmonary Disease (COPD) Patients. (NCT00808288) | Pfizer | 2010-03-01 |
| Characterisation of Healthy Volunteers, Asthma and Chronic Obstructive Pulmonary Disease Patients for Inhalation Profile, Pharyngometry, Spirometric Indices and Lung Morphometry (NCT01345266) | GlaxoSmithKline | 2010-02-01 |
| Effects of Tiotropium on Breathing Capacity and Exercise Limitation in Early Stages of Chronic Obstructive Pulmonary Disease (NCT01072396) | Boehringer Ingelheim | 2010-02-01 |
| Outlook: An Intervention to Improve Quality of Life in Serious Illness (NCT00939146) | Duke University | 2010-02-01 |
| To Evaluate the Safety, Tolerability, Pulmonary Deposition, Pharmacokinetics and Pharmacodynamics of Ciprofloxacin Inhale in Japanese Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD, GOLD II-III) (NCT01072942) | Bayer | 2010-01-01 |
| A Randomized, Double-Blind, 4-way Crossover Study to Evaluate the Efficacy of of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease (NCT01040728) | Boehringer Ingelheim | 2010-01-01 |
| Determining Optimal Free Dose Combination of Tiotropium Bromide and BI 1744 CL in Chronic Obstructive Pulmonary Disease (COPD) (NCT01040403) | Boehringer Ingelheim | 2010-01-01 |
| Effect of Treatment BI 1744 CL (5 and 10 mcg) Versus Placebo on Exercise Endurance Time During Constant Work Rate Cycle Ergometry I (NCT01040130) | Boehringer Ingelheim | 2010-01-01 |
| Chronic Obstructive Pulmonary Disease (COPD) and Osteoporosis (NCT01067248) | Catharina Ziekenhuis Eindhoven | 2010-01-01 |
| Assessment of Chronic Obstructive Pulmonary Disease (COPD) Therapy From the Physicians Perspective Using Tiotropium as an Example (NCT01036763) | Boehringer Ingelheim | 2010-01-01 |
| A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic (PD) Profiles of 3 Doses of Fluticasone Furoate (FF)/GW642444 Inhalation Powder at the End of a 28-day Treatment Period in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Compared to Placebo (NCT01072149) | GlaxoSmithKline | 2010-01-01 |
| Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease (NCT01040689) | Boehringer Ingelheim | 2010-01-01 |
| A Study To Examine The Safety, Pharmacokinetics And Pharmacodynamics Of PF-03635659 In Patients With Chronic Obstructive Pulmonary Disease (NCT01033487) | Pfizer | 2010-01-01 |
| 28-day Repeat Dose Study of GSK573719 (NCT01030965) | GlaxoSmithKline | 2009-12-15 |
| Long-term Physical Training in Chronic Obstructive Pulmonary Disease (NCT01537627) | Universidade Estadual de Londrina | 2009-11-01 |
| Assessment Of The Inhalation Profiles Of Four Dry Powder Inhalers In Patients With Variable Degrees Of Lung Obstruction (NCT01033669) | Pfizer | 2009-11-01 |
| Chronic Obstructive Pulmonary Disease (COPD)-Related Healthcare Utilization and Costs After Discharge From a Hospitalization or Emergency Department Visit on a Regimen of Fluticasone Propionate-Salmeterol Combination Versus Other Maintenance Therapies (NCT01332461) | GlaxoSmithKline | 2009-11-01 |
| Combivent Respimat 1-year Safety Study in Patients With Chronic Obstructive Pulmonary Disease (NCT01019694) | Boehringer Ingelheim | 2009-11-01 |
| Validation of a New Shortness of Breath With Daily Activities Questionnaire in Patients With Chronic Obstructive Pulmonary Disease (NCT00984659) | GlaxoSmithKline | 2009-10-29 |
| Efficacy and Safety Study of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and the Individual Components in Subjects With Chronic Obstructive Pulmonary Disease (COPD) (NCT01054885) | GlaxoSmithKline | 2009-10-19 |
| First Time in Human Study With GSK1325756 (NCT01209052) | GlaxoSmithKline | 2009-10-15 |
| A Study of GSK573719 in Healthy Japanese Male Subjects (NCT01013974) | GlaxoSmithKline | 2009-10-05 |
| Timing of Dilation Tracheostomy in Mechanically Ventilated Chronic Obstructive Pulmonary Disease (COPD) Patients (NCT01021202) | Universitätsklinikum Hamburg-Eppendorf | 2009-10-01 |